JP2020514310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514310A5 JP2020514310A5 JP2019539214A JP2019539214A JP2020514310A5 JP 2020514310 A5 JP2020514310 A5 JP 2020514310A5 JP 2019539214 A JP2019539214 A JP 2019539214A JP 2019539214 A JP2019539214 A JP 2019539214A JP 2020514310 A5 JP2020514310 A5 JP 2020514310A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- use according
- tgf
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003484A JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448800P | 2017-01-20 | 2017-01-20 | |
| EP17305061 | 2017-01-20 | ||
| EP17305061.8 | 2017-01-20 | ||
| US62/448,800 | 2017-01-20 | ||
| PCT/IB2018/000088 WO2018134681A1 (en) | 2017-01-20 | 2018-01-19 | Anti-tgf-beta antibodies and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003484A Division JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514310A JP2020514310A (ja) | 2020-05-21 |
| JP2020514310A5 true JP2020514310A5 (enExample) | 2021-02-18 |
| JP7213186B2 JP7213186B2 (ja) | 2023-01-26 |
Family
ID=61656071
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539214A Active JP7213186B2 (ja) | 2017-01-20 | 2018-01-19 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023003484A Active JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A Active JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A Pending JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003484A Active JP7411832B2 (ja) | 2017-01-20 | 2023-01-13 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2023216508A Active JP7844425B2 (ja) | 2017-01-20 | 2023-12-22 | 抗ｔｇｆベータ抗体およびそれらの使用 |
| JP2025202422A Pending JP2026036696A (ja) | 2017-01-20 | 2025-11-25 | 抗ｔｇｆベータ抗体およびそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10766955B2 (enExample) |
| JP (4) | JP7213186B2 (enExample) |
| CN (2) | CN117417939A (enExample) |
| AU (2) | AU2018209391B2 (enExample) |
| BR (1) | BR112019014787A2 (enExample) |
| CA (1) | CA3050845A1 (enExample) |
| CL (1) | CL2019002011A1 (enExample) |
| CO (1) | CO2019008946A2 (enExample) |
| CR (1) | CR20190375A (enExample) |
| DO (1) | DOP2019000191A (enExample) |
| EC (1) | ECSP19059553A (enExample) |
| IL (3) | IL311866B2 (enExample) |
| MA (1) | MA47311A (enExample) |
| MX (2) | MX2019008551A (enExample) |
| MY (1) | MY200751A (enExample) |
| NZ (1) | NZ796440A (enExample) |
| PE (1) | PE20200734A1 (enExample) |
| PH (1) | PH12019501635A1 (enExample) |
| SG (1) | SG11201906660TA (enExample) |
| TW (3) | TW202506185A (enExample) |
| UY (1) | UY37575A (enExample) |
| ZA (1) | ZA201904494B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| BR112021000065A2 (pt) * | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| WO2020047333A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| AU2019406214A1 (en) * | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| EP3739588A1 (en) * | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| CN116670163A (zh) | 2020-02-11 | 2023-08-29 | Hcw生物科技公司 | 治疗年龄相关疾病和炎性疾病的方法 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| AU2021262794B2 (en) | 2020-04-29 | 2026-06-18 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| TW202317185A (zh) | 2021-06-18 | 2023-05-01 | 美商健臻公司 | 抗ＴＧＦ－β抗體配製品及其用途 |
| JP7892764B2 (ja) | 2021-08-11 | 2026-07-21 | イミュニティーバイオ インコーポレイテッド | 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用 |
| CN115707716A (zh) * | 2021-08-18 | 2023-02-21 | 丹生医药技术(上海)有限公司 | 一种TGF-β/VEGF双功能抗体融合蛋白 |
| US20230144192A1 (en) * | 2021-11-01 | 2023-05-11 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
| EP4507712A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder |
| US12594323B2 (en) | 2022-04-13 | 2026-04-07 | Immunitybio, Inc. | Methods of reducing neuroinflammation |
| CN115508565B (zh) * | 2022-10-20 | 2024-11-15 | 成都医学院第一附属医院 | Cilp1作为肾纤维化生物标志物的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| CA2280957A1 (en) | 1997-02-14 | 1998-08-20 | Leslie Orgel | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| MY131805A (en) | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
| EP1074563A1 (en) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20020063763A1 (en) | 2000-11-29 | 2002-05-30 | Mantell David Allen | Apparatus and method for removing air bubbles from an ink jet printhead |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| KR20050094832A (ko) | 2002-12-31 | 2005-09-28 | 알투스 파마슈티컬스 인코포레이티드 | 단백질 결정과 이온성 중합체를 함유하는 복합체 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| PL1759001T3 (pl) | 2004-04-21 | 2011-09-30 | Alexion Pharma Inc | Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości |
| CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
| TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| LT2691417T (lt) * | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| MX361773B (es) | 2012-05-31 | 2018-12-17 | Innate Pharma | Agentes de ligación a tlr3. |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA2886607A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| AU2014235933B2 (en) * | 2013-03-20 | 2019-01-24 | Baylor College Of Medicine | Methods for treating osteogenesis imperfecta |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EP3119419B1 (en) | 2014-03-17 | 2019-04-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| ES2820768T3 (es) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| HRP20201334T1 (hr) | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| US20190216943A1 (en) | 2016-08-11 | 2019-07-18 | Precithera, Inc. | Tgf-beta antagonist conjugates |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
-
2018
- 2018-01-18 TW TW113140547A patent/TW202506185A/zh unknown
- 2018-01-18 TW TW107101789A patent/TWI787230B/zh active
- 2018-01-18 TW TW111145565A patent/TWI856437B/zh active
- 2018-01-19 BR BR112019014787-0A patent/BR112019014787A2/pt unknown
- 2018-01-19 NZ NZ796440A patent/NZ796440A/en unknown
- 2018-01-19 MA MA047311A patent/MA47311A/fr unknown
- 2018-01-19 CN CN202311230922.7A patent/CN117417939A/zh active Pending
- 2018-01-19 MY MYPI2019003989A patent/MY200751A/en unknown
- 2018-01-19 IL IL311866A patent/IL311866B2/en unknown
- 2018-01-19 MX MX2019008551A patent/MX2019008551A/es unknown
- 2018-01-19 JP JP2019539214A patent/JP7213186B2/ja active Active
- 2018-01-19 CR CR20190375A patent/CR20190375A/es unknown
- 2018-01-19 IL IL268112A patent/IL268112B2/en unknown
- 2018-01-19 PE PE2019001465A patent/PE20200734A1/es unknown
- 2018-01-19 CA CA3050845A patent/CA3050845A1/en active Pending
- 2018-01-19 CN CN201880007975.3A patent/CN110520441B8/zh active Active
- 2018-01-19 AU AU2018209391A patent/AU2018209391B2/en active Active
- 2018-01-19 US US15/875,532 patent/US10766955B2/en active Active
- 2018-01-19 UY UY0001037575A patent/UY37575A/es not_active Application Discontinuation
- 2018-01-19 SG SG11201906660TA patent/SG11201906660TA/en unknown
-
2019
- 2019-07-09 ZA ZA2019/04494A patent/ZA201904494B/en unknown
- 2019-07-12 PH PH12019501635A patent/PH12019501635A1/en unknown
- 2019-07-17 MX MX2023002588A patent/MX2023002588A/es unknown
- 2019-07-18 CL CL2019002011A patent/CL2019002011A1/es unknown
- 2019-07-19 DO DO2019000191A patent/DOP2019000191A/es unknown
- 2019-08-16 CO CONC2019/0008946A patent/CO2019008946A2/es unknown
- 2019-08-19 EC ECSENADI201959553A patent/ECSP19059553A/es unknown
-
2020
- 2020-07-16 US US16/931,198 patent/US11242384B2/en active Active
-
2021
- 2021-12-23 US US17/561,510 patent/US12049496B2/en active Active
-
2023
- 2023-01-13 JP JP2023003484A patent/JP7411832B2/ja active Active
- 2023-12-22 JP JP2023216508A patent/JP7844425B2/ja active Active
-
2024
- 2024-07-09 US US18/767,270 patent/US20250026821A1/en active Pending
- 2024-11-13 AU AU2024264593A patent/AU2024264593A1/en active Pending
-
2025
- 2025-10-05 IL IL323799A patent/IL323799A/en unknown
- 2025-11-25 JP JP2025202422A patent/JP2026036696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (enExample) | ||
| JP2020099324A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2022510964A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2020516240A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018508483A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017514461A5 (enExample) | ||
| JP2023507190A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2021531255A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2010535713A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2025092589A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2022512851A5 (enExample) |